

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Steven D. Nathan, M.D.

Committee: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee

Meeting Dates: November 1, 2022

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda items described below, I may be considered for participation in the advisory committee meeting.

On November 1, 2022, the committee will discuss ongoing concerns that pulse oximeters may be less accurate in individuals with darker skin pigmentations. The advisory panel will discuss factors that may affect pulse oximeter accuracy and performance, the available evidence about the accuracy of pulse oximeters, recommendations for patients and health care providers, the amount, and type of data that should be provided by manufacturers to assess pulse oximeter accuracy and to guide other regulatory actions as needed.

Type of Interest	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/Investment	Financial interests in healthcare sector mutual funds	Aggregate value of \$200,000-\$300,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/S/	October 6, 2022
Signature	Date

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov